OVERVIEW
Happy Saturday
Welcome to the Stocks Top 25 Newsletter this week!
The Stocks Top 25 reports the 25 best-performing stocks in the S&P 500, Nasdaq 100, and Russell 2000 year to date (YTD) and tracks their performances over time. To help you understand this data further, check out our FAQ page, and feel free to reach out if you have questions!
Here are the Stocks Top 25 Lists for this week:
S&P 500
Top 25 S&P 500
The S&P 500 Top 25 list (+0.74%) underperformed the S&P 500 index (+2.25%).
There were 1 major changes to the list this week.
NASDAQ 100
The Large-Cap Nasdaq 100
The Nasdaq 100 Top 25 list (+0.32%) underperformed the Nasdaq 100 index (1.87%).
There was 3 major changes to the list this week.
RUSSELL 2000
The Growth-Centric Russell 2000
The Russell 2000 Top 25 list (+0.39%) underperformed the Russell 2000 index (+3.54%).
There were 5 major changes to the list this week.
Top Dawg Of The Week
The Top 25 list's Top Dawg was $AGEN ( ▲ 10.16% ) , which rallied 27%.
The firm is a Massachusetts-based clinical-stage company specializing in cancer and infectious disease treatments.
The firm was removed from the Russell 2000 Value Index according to Market Screener. On the 30th, the firm requested a dismissal of a lawsuit filed by investors alleging that the firm advertised that its therapy trials had a higher chance of success for FDA approval than they actually did, according to a Trading View news update.
On Monday, a B.Riley Financial analyst named Mayank Mamtani updated the stock with a maintained buy rating, with a target price of $8.
According to TipRanks data, the analyst has a success rate of 28.2% and a total average return of -11.8% over the past year.
Agenus is up 121% YTD.
Stocks user sentiment was drifting higher on the stock